Bayer beefs up Ob/Gyn sales calls

Share this article:
Bayer runs "corrective" Yaz ad, agrees to preclearance
Bayer runs "corrective" Yaz ad, agrees to preclearance
Pfizer has usurped Merck as the most admired drug company among obstetricians and gynecologists, according to SDI's Pharmaceutical Company Image 2011 study, while Bayer increased its sales presence in that specialty significantly.

Bayer came in second among Ob/Gyns asked to name three pharma firms they considered “top companies (it was fourth last year),” followed by Merck and Warner Chilcott, which called on Ob/Gyns more than any other corporation during the year to April 2011, accounting for 13% of all sales calls to those docs.

Warner Chilcott was followed in volume of calls by Bayer, which made 12% of all sales calls – up 19%, for that year-to-April period, over the previous 12 months.

“Bayer's improved standing is impressive, particularly over only one year's time,” said SDI's Jason Fox, associated director, Syndicated Analytics group. “The company's reps have increased their presence among Ob/Gyns and must be making a positive impression.”

Bayer reps were most likely to discuss two newer contraceptives, Beyaz or Natazia, or Yaz during those visits. Beyaz was discussed during 30% of the company's details to Ob/Gyns, Natazia in 24% and Yaz in 19%.

Teva and Pfizer each accounted for 7% of sales calls to Ob/Gyns and Merck 5%.

The survey of 9,800 physicians, including 385 Ob/Gyns, also found that perception of the pharma industry improved among physicians in general for the first time since 2004, however meagerly, as 58% of respondents reported a somewhat positive or extremely positive impression – up two points over 2010.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...